QIAGEN welcomes approval of scheme by supreme court of Victoria
Venlo, The Netherlands, August 9, 2011 - QIAGEN N.V. ("QIAGEN") welcomes today's announcement by Cellestis Limited ("Cellestis") that the Supreme Court of Victoria has approved QIAGEN's acquisition of all of the ordinary shares in Cellestis shares by way of a scheme of arrangement ("Scheme").
Once the Scheme is implemented, eligible Cellestis shareholders will receive total cash consideration of A$3.80 per share. This will be comprised of cash from QIAGEN of A$3.73 per Cellestis share and a special dividend of 7 cents per Cellestis share (declared by Cellestis on 4 August 2011).
Further details regarding the Scheme are set out in Cellestis' announcement earlier today.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs nearly 3,600 people in over 35 locations worldwide. Further information about QIAGEN can be found at http://www.qiagen.com/.